Nasdaq-listed Anixa Biosciences board approves purchase of Bitcoin as reserve asset
Anixa Biosciences, a Nasdaq-listed company, has approved the purchase of Bitcoin as a reserve asset. The company also reiterated its ongoing stock buyback plan. Amit Kumar, CEO of the company, stated that the decision regarding Bitcoin is another way of prudent financial management and can achieve higher shareholder value. Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Abu Dhabi-backed VC firm invests $5 million in ZKsync-based crypto exchange GRVT
GRVT has raised $5 million in equity funding from Further Ventures, a VC firm backed by Abu Dhabi’s sovereign wealth fund, ADQ.The ZKsync-based hybrid crypto exchange recently launched its mainnet alpha — initially offering perpetual trading.
Bitcoin Fades From Highs After No Crypto Mentions During Trump's Inauguration Speech
Massive Whale Activity: Best Altcoins to Buy Now For January – Cryptos Picked by Whales (500x Potential Returns)
Trending news
MoreCrypto prices
More
